Accelerating the Next Wave of RNA Editing Drugs to Patients

RNA editing is emerging as a powerful tool and therapeutic modality, with Wave Life Sciences announcing positive clinical data for AATD, and a new wave of companies entering the clinic; the aspiration of bringing efficacious editors to patients is ever closer to becoming a reality. 

With the forging of important partnerships like Eli Lilly and Rznomics, and significant funding rounds like AIRNA’s $155m oversubscribed series B, the 6th RNA Editing Summit couldn’t have come at a better time, and returned to Boston in July 2025 to advance the discovery and development of RNA modifying therapies.  

Uniting 60+ RNA editing leaders from the likes of Korro Bio, Shape Therapeutics, Eli Lilly, Deep Genomics, Novo Nordisk, HuidaGene Therapeutics, and more, this intimate, focused forum showcased novel, innovative editing technologies, translational and functional biology, and never-before-seen clinical data.  

You could have joined your peers in Platform Biology, Chemistry, and R&D, for an unrivaled learning and networking opportunity to robustly accelerate more pre-clinical RNA editing candidates towards clinical development, as we see the next wave of editors moving closer to patients in need.